Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-targeted CAR-T in Relapsed/Refractory B-cell Lymphoma
NCT07093086Phase 1Withdrawn
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in B cell lymphoma, sponsored by Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd. Primary endpoints: Incidence of Adverse Events at 28 days, Objective Response Rate at 2 years and 3 more. Planned start Nov 2024; status: withdrawn.
02
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT07093086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07093086.